EagleClaw Capital Management’s Pfizer PFE Stock Holding History

EagleClaw Capital Management’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$3.12M	Buy	111,043 +82,275	+286%	+$2.19M	0.44%	56
2025 Q4	$716K	Buy	28,768 +3,100	+12%	+$78.2K	0.1%	101
2025 Q3	$654K	Sell	25,668 -750	-3%	-$18.5K	0.09%	103
2025 Q2	$640K	Sell	26,418 -863	-3%	-$20.1K	0.1%	100
2025 Q1	$691K	Buy	27,281 +100	+0.4%	+$2.62K	0.11%	98
2024 Q4	$721K	Sell	27,181 -463	-2%	-$12.6K	0.11%	96
2024 Q3	$800K	Sell	27,644 -750	-3%	-$21.9K	0.13%	93
2024 Q2	$794K	Hold	28,394	–	–	0.14%	92
2024 Q1	$788K	Buy	28,394 +1,000	+4%	+$27.7K	0.14%	92
2023 Q4	$789K	Hold	27,394	–	–	0.16%	89
2023 Q3	$909K	Hold	27,394	–	–	0.21%	83
2023 Q2	$1M	Sell	27,394 -2,015	-7%	-$78.4K	0.23%	80
2023 Q1	$1.2M	Hold	29,409	–	–	0.28%	76
2022 Q4	$1.51M	Hold	29,409	–	–	0.36%	72
2022 Q3	$1.29M	Buy	29,409 +1,401	+5%	+$68.1K	0.36%	70
2022 Q2	$1.47M	Sell	28,008 -1,726	-6%	-$88K	0.4%	67
2022 Q1	$1.54M	Sell	29,734 -825	-3%	-$42.8K	0.35%	68
2021 Q4	$1.8M	Buy	30,559 +600	+2%	+$29.7K	0.4%	63
2021 Q3	$1.29M	Buy	29,959 +625	+2%	+$27.7K	0.33%	69
2021 Q2	$1.15M	Hold	29,334	–	–	0.3%	71
2021 Q1	$1.06M	Buy	29,334 +950	+3%	+$33.7K	0.31%	71
2020 Q4	$1.04M	Sell	28,384 -7,014	-20%	-$257K	0.33%	68
2020 Q3	$1.23M	Buy	35,398 +6,762	+24%	+$237K	0.43%	62
2020 Q2	$888K	Sell	28,636 -16,658	-37%	-$566K	0.34%	67
2020 Q1	$1.4M	Buy	45,294 +949	+2%	+$32.3K	0.66%	49
2019 Q4	$1.65M	Buy	44,345 +14,749	+50%	+$525K	0.6%	56
2019 Q3	$1.01M	Buy	29,596 +13,571	+85%	+$493K	0.41%	67
2019 Q2	$657K	Sell	16,025 -144	-0.9%	-$5.72K	0.29%	79
2019 Q1	$649K	Hold	16,169	–	–	0.3%	81
2018 Q4	$670K	Buy	16,169 +316	+2%	+$13.1K	0.35%	71
2018 Q3	$662K	Buy	15,853 +7,772	+96%	+$299K	0.29%	75
2018 Q2	$278K	Buy	8,081 +132	+2%	+$4.51K	0.13%	100
2018 Q1	$268K	Hold	7,949	–	–	0.14%	100
2017 Q4	$273K	Buy	+7,949	New	+$271K	0.14%	100

Other funds holding PFE

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

State Farm Mutual Automobile Insurance Bloomington, Illinois $127B AUM 32.55% 1-Year Est. Return

EagleClaw Capital Management's PFE Position: Q1 2026 in Review

EagleClaw Capital Management increased its Pfizer (PFE) stake by 286% in Q1 2026, buying an estimated $2.19M and bringing the position to 111,043 shares worth $3.12M. The position accounts for 0.44% of the portfolio, ranked #56.

EagleClaw Capital Management first reported a position in PFE in Q4 2017 and has held it in 34 quarters since. 2,939 funds tracked by Wall St. Rank hold PFE as of Q1 2026.

EagleClaw Capital Management held 111,043 shares of Pfizer worth $3.12M as of Q1 2026.
EagleClaw Capital Management bought 82,275 Pfizer shares in Q1 2026, an estimated $2.19M.
Pfizer made up 0.44% of EagleClaw Capital Management's portfolio in Q1 2026, its #56 holding.
EagleClaw Capital Management first reported a position in Pfizer in Q4 2017 and has held it in 34 quarters since.
2,939 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.

Based on EagleClaw Capital Management's 13F filing for Q1 2026, filed 8 May 2026.